Trump's Psychedelics Executive Order Is Really a State-Match Program

On April 18, President Trump signed an executive order directing the FDA to fast-track review of psychedelic drugs for serious mental illness. The headline was the drugs. The more durable story is the $50 million state-matching mechanism — and the VA integration that sits underneath it.

The executive order Trump signed Saturday morning in the Oval Office — flanked by HHS Secretary Robert F. Kennedy Jr., FDA Commissioner Marty Makary, former Navy SEAL Marcus Luttrell, and podcaster Joe Rogan — marked a substantive step forward for veterans seeking access to promising mental health treatments.^PSY-1 The ceremony drew national attention to a long-running advocacy effort led by special operations veterans, many of whom had traveled abroad for ibogaine treatment before FDA-authorized pathways existed. The order's provisions are narrower and more structural than the signing coverage conveyed, and worth reading closely.

The EO does four things. First, it directs the FDA Commissioner to issue Commissioner's National Priority Vouchers to psychedelic drugs that have already received Breakthrough Therapy designations — a review-prioritization mechanism that shortens FDA review times from months to weeks.^PSY-2 Makary confirmed the FDA will issue national priority vouchers for three psychedelic drugs this week.^PSY-3 Second, it directs FDA and DEA to establish a pathway for eligible patients to access investigational psychedelics — including ibogaine — under the framework of the Right to Try Act. Third, it requires HHS, through ARPA-H, to allocate at least $50 million to match state government investments in psychedelic research for populations with serious mental illness.^PSY-2 Fourth, it directs HHS, FDA, and the VA to sign data-sharing memoranda and coordinate on clinical trial participation, with particular focus on veteran populations.^PSY-2

The Veteran Framing Is Load-Bearing

The political center of the order is veteran mental health. Trump cited a 2024 Stanford study of 30 special operations veterans with traumatic brain injuries who underwent ibogaine treatment and reported reductions of 88% in PTSD, 87% in depression, and 81% in anxiety symptoms within a month.^PSY-4 The EO explicitly requires HHS, FDA, and the VA to coordinate, and the VA is already participating in at least five psychedelic clinical trials in New York, California, and Oregon.^PSY-1

The veteran suicide data is the backdrop Kennedy and Trump are working against. In 2023, 6,398 veterans died by suicide — 44 fewer than the prior year, and the second-lowest annual total in the past fifteen years. Suicide rates for veterans remain more than twice as high as for non-veteran adults. The most frequently identified risk factor among veterans who died by suicide from 2021 to 2023, by VA's own accounting, was pain.^PSY-5

What the EO Actually Changes

Several things are worth separating. The Right to Try pathway for investigational psychedelics is operationally meaningful for a narrow population of terminally ill patients — it is not a general access expansion. The rescheduling language applies only after successful completion of Phase 3 trials and FDA approval; no drug in the current pipeline is positioned to benefit immediately. The National Priority Vouchers are substantive: they shorten FDA review times and will likely accelerate the first approvals of MDMA-assisted therapy (for PTSD) and psilocybin (for treatment-resistant depression), both of which already have Breakthrough Therapy designations.

The $50 million ARPA-H state-match, however, is the most interesting piece for anyone tracking state health policy. It is a matching fund — states that appropriate dollars for psychedelic research get federal money; states that do not, do not. Texas launched a $50 million state ibogaine research consortium in 2025; Oregon and Colorado have psilocybin therapy programs. Those three states are positioned to capture federal match immediately. Every other state is not.^PSY-2

The FY 2027 Budget Proposes Eliminating Rural Health Programs. Congress Will Probably Say No Again.

The President's Budget Request is a wish list, not a law. This year's list eliminates the Flex Program, State Offices of Rural Health, and a $102 million chunk of the Federal Office of Rural Health Policy. Congress rejected nearly identical proposals last cycle.

On April 3, the Office of Management and Budget released the President's FY 2027 Budget Request. It calls for $111.1 billion in discretionary funding for HHS — a 12.5% reduction from FY 2026 — and revives the proposed consolidation of SAMHSA, HRSA, and portions of the CDC into a new Administration for a Healthy America.^FY-1 Congress rejected this structure last cycle. It is being proposed again.^FY-2

For rural health specifically, the proposed cuts are severe on paper. The budget would eliminate State Offices of Rural Health, the Medicare Rural Hospital Flexibility Program (Flex), the Rural Hospital Stabilization Program, and the Rural Hospital Provider Assistance Program. It proposes a $102 million cut to the Federal Office of Rural Health Policy.^FY-3 The National Rural Health Association responded on April 3 with a formal statement of opposition.^FY-4

Why This Is Probably Not What Will Happen

The President's Budget Request is a proposal. It is not an appropriation. Congress has rejected structurally similar proposals in each of the last several budget cycles, including last year's proposed 40% cut to NIH. This year's proposed 10% NIH cut has already been flagged by appropriators as unlikely to advance.^FY-5 Rural health programs have an unusual amount of bipartisan protection — they matter to red-state senators from Iowa, Kansas, Nebraska, South Dakota, Montana, and North Dakota, and those senators historically protect the Flex Program, SORHs, and FORHP even under administrations of their own party.

HHS Secretary Kennedy is scheduled to appear before six congressional committees in April to defend the budget request. He will face questions on vaccine policy, on the ACIP vacancy situation following Vice Chair Robert Malone's resignation, and on proposed rural health cuts.^FY-2 The most likely outcome of these hearings is the same outcome as last cycle: Congress funds the programs the administration proposed to eliminate, at roughly the same levels as the previous year.

CMS Finalized the 2027 Medicare Advantage Rate Notice. Insurers Got $13 Billion.

The rule reverses a Biden-era reform that would have reduced overpayments. For rural providers contracted with MA plans, it changes the bargaining math — the plans have more money.

CMS finalized its 2027 Medicare Advantage rate notice on April 6, raising payments to MA plans by an effective rate that will funnel an additional $13 billion to insurers in CY 2027 compared to current-law baseline.^MA-1 The final rule abandons a proposed reform — originally advanced during the Biden administration — that would have reduced MA overpayments by recalibrating risk-adjustment for certain diagnoses the industry had been systematically over-coding.^MA-1

This is worth understanding in context. Medicare Advantage now covers roughly 34 million beneficiaries — about 54% of all Medicare enrollees. In rural areas, MA penetration has grown rapidly but unevenly. In North Dakota, MA penetration sits at roughly 34%, below the national average but up substantially from five years ago. For rural hospitals, that means an increasing share of Medicare revenue runs through commercial plans negotiating contracts annually — not through traditional Medicare fee-for-service.^MA-2

Why Rural Providers Have a Mixed Relationship With MA

Medicare Advantage plans pay rural providers at rates broadly comparable to traditional Medicare, but the administrative load is different. MA plans use prior authorization aggressively, deny claims at higher rates, and require in-network contracting that smaller rural providers may lack the bargaining leverage to negotiate favorably. The Critical Access Hospital cost-based reimbursement model that makes rural hospitals financially viable under traditional Medicare does not fully apply to MA plans, which negotiate independently — and which have been moving rapidly toward prospective payment arrangements that leave rural providers exposed to stop-loss risk they are not sized to absorb.

The 2027 rate increase does not directly change what MA plans pay rural providers. It changes what CMS pays the plans. But indirectly, it matters: plans that are better-funded have more room in their contracts, and the annual MA contract negotiation cycle that opens this summer will happen in that context. Rural providers entering 2027 MA negotiations should come in knowing their counterparty is $13 billion better-funded than last year.

Round 1 Closes April 30. What Comes Next — and Where EMS Fits.

The first RHTP funding opportunity closes in ten days. Rounds 2–3 are expected mid-2026 and will almost certainly include EMS. If you're an EMS agency or rural hospital operating ambulance service, now is the time to position.

North Dakota HHS announced the first RHTP funding opportunity on March 18, 2026 — a $10 million workforce retention fund restricted to the state's 37 Critical Access Hospitals and their owned or operated clinics, with an estimated 37 awards of approximately $270,000 each.^ND-1 EMS agencies were not eligible for Round 1. That is a legitimate source of frustration across the ND EMS Association membership, where rural ambulance services are facing the same staffing and financial pressures the Round 1 funds are designed to address at CAHs.

The structural logic behind the exclusion is that Round 1 is narrowly scoped to workforce retention at Medicare-certified CAH entities. EMS sits outside that perimeter. But EMS is explicitly named in ND HHS's approved RHTP project narrative as a Rounds 2–3 priority — with "EMS stabilization" listed among the programmatic commitments the state made to CMS in its application.^ND-2

What EMS Agencies Can Do Now

Three things. First, get organized. The ND EMS Association has been active on RHTP engagement and is the right aggregation point for Rounds 2–3 input. Agencies that want to shape the Request for Proposals should be in conversation with NDEMSA leadership now, not after the announcement.^ND-3 Second, align with a CAH. The clearest path for EMS agencies into RHTP funding is through partnership with a Critical Access Hospital that can serve as the applicant of record on joint initiatives — community paramedic programs, coordinated dispatch, shared training infrastructure. Round 1 includes CAH-affiliated entities; Rounds 2–3 are likely to broaden that perimeter. Third, document your case. The most effective Rounds 2–3 applications will come from agencies that can show what they are currently losing money on, what they need to stabilize, and what outcomes investment would produce. The ND EMS system is already under pressure; agencies that have their numbers in order will be positioned first.